ANTX - Company ID 0001880438
AN2 Therapeutics, Inc. trades as ANTX. This page tracks AN2 Therapeutics, Inc. through 358 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Next research step
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-11 |
| Major company event | 8-K | 2026-05-11 |
| Annual report to shareholders | ARS | 2026-04-22 |
| Proxy materials | DEFA14A | 2026-04-22 |
| Proxy statement | DEF 14A | 2026-04-22 |
| EFFECT | - | 2026-04-20 |
| 424B3 | - | 2026-04-20 |
The largest companies sharing AN2 Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
In its latest fiscal year AN2 Therapeutics, Inc. reported a net loss of $35.17M.